Sigrid S Skånland

19PUBLICATIONS
89CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 10, 2026
Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.

|Jan 22, 2026
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity.

Elise Solli, Alessio Bevilacqua, Mathias Wenes

|Jul 23, 2025
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient.

Johanne U Hermansen, Paschalis Athanasiadis, Yanping Yin

|Jul 09, 2025
Targeting proteostasis in multiple myeloma through inhibition of LTK.

Thea Kristin Våtsveen, Mariaserena Giliberto, Valgerdur Bjornsdottir

|Mar 14, 2025
Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia.

Yanping Yin, Haifeng Xu, Liye He

|Jan 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.

Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast

Pageof 4

Frequent Collaborators

9 joint publications

Kjetil Taskén

4 joint publications

Johanne U Hermansen

4 joint publications

Geir E Tjønnfjord

3 joint publications

Tero Aittokallio